Inotrem successfully completes its first phase I clinical trial with Motrem, a TREM-1 pathway modulator for the treatment of septic shock.
September 13, 2016
Paris, France, September 13, 2016 – Inotrem SA, a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today